Courtesy of Dr. Carlos Fava.
We are well aware that both transcatheter aortic valve replacement (TAVR) and surgical valve replacement (SAVR) generate bleeding (15% to 22% for TAVR and 22% to 44% for SAVR).
Frail patients constitute a particular group. These have not yet been assessed as to the real risk they run and mortality with each of these strategies.
A sub-analysis of the FRAILTY-AVR was carried out, including 1,195 frail patients. 747 received TAVR and 448 received SAVR (238 patients were combined with CABG) presenting major or life-threatening bleeding vs. patients who did not receive either of these.
Mean age was higher in TAVR patients (83 vs. 77 years) as was STS: 6.1 vs. 3.4.
TAVR patients presented less life-threatening bleeding (3% vs. 8%), major bleeding with clinically apparent source (6% vs. 10%) and major bleeding without clinically apparent source (9% vs. 31%). In addition, they have less need for transfusion (0.9 vs. 2.8 units). Patients undergoing concomitant CABG presented higher bleeding rate.
Read also: Antiaggregation vs. Anticoagulation after Peripheral PCI.
Mortality at 30 days was higher in patients presenting bleeding with both strategies.
At one year follow-up, major bleeding was associated to a three-fold increase in mortality, both for TAVR (36% vs. 14% odds ratio: 3.40; 95% confidence interval: 2.22 to 5.21) and SAVR (11% vs. 4% odds ratio: 2.79; 95% confidence interval: 1.25 to 6.21).
Conclusion
Frailty is associated to post-procedural major bleeding in elderly adults undergoing TAVR or SAVR, ad with higher mid-term mortality.
Courtesy of Dr. Carlos Fava.
Original Title: Frailty and Bleeding in Older Adults Undergoing TAVR or SAVR Insights From the FRAILTY-AVR Study.
Reference: Melissa Bendayan, et al. J Am Coll Cardiol Intv 2020;13:1058–68.
Subscribe to our weekly newsletter
Get the latest scientific articles on interventional cardiology
We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.